Intrinsic Imaging

FDA Audited

Intrinsic Imaging’s FDA Establishment Identifier (FEI) is 3013568226.

Intrinsic Imaging has successfully completed three FDA inspections spanning both medical device and pharmaceutical clinical trials.

Each inspection concluded with zero Form FDA 483 observations. This consistent regulatory performance demonstrates the strength and effectiveness of our Quality Management System, operational controls, documentation practices, and commitment to data integrity.

Our inspection history reflects a culture of quality embedded throughout our organization and our ability to consistently operate within rigorous regulatory requirements. From imaging acquisition and data management to independent image review and study documentation, our processes are designed to support inspection readiness and maintain the highest standards of quality and compliance throughout the clinical trial lifecycle.

Quality director beside a monitor showing an oncology central read of pelvic MRI with measurements and an audit trail ending in electronic signature, quality-system binders in the foreground
DetailFDA Inspection #1FDA Inspection #2FDA Inspection #3
DateAugust 2012August 2018January 2021
FDA CenterCenter for Devices Radiological HealthCenter for Drug Evaluation BIMO Compliance ProgramCenter for Drug Evaluation BIMO Compliance Program
Trial TypeMedical Device – AI/CADDrugDrug
Therapeutic AreaOncologyOncologyOncology
Auditors1 Auditor1 Auditor2 Auditors
Duration5-man days5-man days8-man days
Inspection ID79325710643681134748
End Date08/03/201208/10/201801/07/2021
FDA Establishment Identifier (FEI)300957379630135682263013568226
Address8401 Datapoint Dr Ste 600, San Antonio, TX 78229580 Main St Ste 210, Bolton, MA 01740580 Main St Ste 210, Bolton, MA 01740
Project AreaBioresearch MonitoringBioresearch MonitoringBioresearch Monitoring
Product TypeDevicesDrugsDrugs
ClassificationNAINAINAI
ResultZero 483 ObservationsZero 483 ObservationsZero 483 Observations
Press ReleaseRead the August 2012 press releaseRead the August 2018 press releaseRead the January 2021 press release

FDA Inspected — a record of regulatory excellence.

What Our Inspection Record Means for Sponsors

Our inspections were conducted by both the Center for Devices and Radiological Health and the Center for Drug Evaluation's Bioresearch Monitoring (BIMO) Compliance Program, covering medical device, AI/CAD and drug oncology trials. Completing each with zero 483 observations gives sponsors confidence that the imaging data supporting their regulatory submissions was collected, reviewed and documented under controlled, auditable processes.

This record is supported by our Quality Management System, certified by the British Standards Institution (BSI) to ISO 9001 and ISO 13485, alongside ISO 22301, ISO 27001 and ISO 27018 certifications for business continuity, information security and protection of personal data. Together, these standards help ensure your trial's imaging endpoints are inspection-ready from study start-up to database lock.

Imaging Study Records for Inspection Readiness

Inspection readiness is maintained through the study, not assembled only when an inspection is announced. Our imaging workstream preserves the records needed to explain how an endpoint was acquired, assessed and delivered.

From Source Image to Final Endpoint

A traceable review history connects the examination, quality checks, reader assessment, adjudication and final data transfer. Charter versions, acquisition instructions, qualification records and query resolution provide context for those decisions. Sponsor reconciliation confirms that delivered results match the agreed study scope.

Supporting Sponsor Audits and Regulatory Questions

We support review of imaging methods, controlled processes and study records, including explanations of blinding, missing examinations and endpoint derivation. Our prior zero-483 inspection outcomes describe those inspections; they are not FDA endorsement of a product or a guarantee of a future inspection result.

Frequently Asked Questions

How do I book a meeting with Intrinsic Imaging at a conference?
Use the Book a time with us form on the Events page to tell Intrinsic Imaging which meeting you are attending and a good day and time. Intrinsic Imaging will confirm a place to meet.
What are Intrinsic Imaging’s typical image receipt and quality control timelines?
Intrinsic Imaging typically confirms image receipt on the same business day as site upload and issues a quality-control result or query within 24–48 hours of upload. Intrinsic Imaging measures the quality-control milestone at issuance of the result or query, rather than at resolution of every outstanding site query.
Which gastrointestinal indications does Intrinsic Imaging support?
Intrinsic Imaging’s gastrointestinal experience includes IBD, ulcerative colitis, GERD, IBS, short bowel syndrome, ulcers and related abdominal and pelvic conditions.
Go to more Frequently Asked Questions

Tell us about your trial.

Our team will respond within one business day.